Skip to main content
Vitamin D Deficiency: "At Risk" Patient Populations and Potential Drug Interactions
Marshall Journal of Medicine
  • Dana Lycans, MD, Marshall University
  • Elias Salloum, MD, Marshall University
  • Matthew K Wingate, MD, Marshall University
  • Thomas Melvin, MD, Marshall University
  • Grant S Buchanan, MD, Marshall University
  • Franklin D. Shuler, MD, PhD, Marshall University

Vitamin D is known to play an essential role in calcium homeostasis; however, excessive amounts can have harmful effects. Calcium and vitamin D levels are known to be influenced by drug interactions and pathology ranging from of cancer to cardiovascular disease. Vitamin D supplementation has become widespread, and it is important for clinicians to understand the way that certain conditions and medications interact with vitamin D and calcium homeostasis. The purpose of this review is to outline the benefits and adverse effects of vitamin D and how its levels are affected by certain pathologic and pharmacologic interactions.

Conflict(s) of Interest
All authors have no conflicts of interest to disclose.
References with DOI

1. Guyton AC, Hall, J.E. Textbook of medical physiology. 10th ed. Philadelphia: Saunders; 2000.

2. Barrett KE. Ganong's review of medical physiology. 23rd ed. New York: McGraw-Hill Medical; 2010.

3. Boron WF. Medical physiology: a cellular and molecular approach. 2nd ed. Philadelphia: Saunders/Elselvier; 2009.

4. Kronenberg HM, Lanske B, Kovacs CS, Chung UI, Lee K, Segre GV, et al. Functional analysis of the PTH/PTHrP network of ligands and receptors. Recent progress in hormone research. 1998;53:283-301; discussion -3.

5. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. The Journal of endocrinology. 1997;154 Suppl:S57-73.

6. Shuler FD, Lycans D, Salloum E. Extraskeletal effects of vitamin D: potential impact on WV disease morbidity and mortality. The West Virginia medical journal. 2012;108(3):56-62.

7. Koroshi A, Idrizi A. Renoprotective effects of Vitamin D and renin-angiotensin system. Hippokratia. 2011;15(4):308-11.

8. Talmor Y, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. European journal of clinical investigation. 2008;38(8):548-54.

9. Pilz S, Tomaschitz A, Drechsler C, Dekker JM, Marz W. Vitamin D deficiency and myocardial diseases. Molecular nutrition & food research. 2010;54(8):1103-13.

10. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. The British journal of nutrition. 2005;94(4):483-92.

11. Mitsuhashi T, Morris RC, Jr., Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. The Journal of clinical investigation. 1991;87(6):1889-95.

12. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. The American journal of clinical nutrition. 2003;77(1):204-10.

13. Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. The Journal of biological chemistry. 2004;279(34):35798-802.

14. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension. 2008;52(5):847-55.

15. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267(5):462-72.

16. van Ballegooijen AJ, Gansevoort RT, Lambers-Heerspink HJ, de Zeeuw D, Visser M, Brouwer IA, et al. Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study. Hypertension. 2015.

17. Beveridge LA, Witham MD. Controversy in the link between vitamin D supplementation and hypertension. Expert review of cardiovascular therapy. 2015:1-3.

18. Shuler FD, Schlierf T, Wingate M. Preventing falls with vitamin D. The West Virginia medical journal. 2014;110(3):10-2.

19. Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2004;19(2):265-9.

20. Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcified tissue international. 2000;66(6):419-24.

21. Schott GD, Wills MR. Muscle weakness in osteomalacia. Lancet (London, England). 1976;1(7960):626-9.

22. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2009;339:b3692.

23. Hansen KE, Johnson R, Chambers KR, et al. Treatment of vitamin d insufficiency in postmenopausal women: A randomized clinical trial. JAMA Internal Medicine. 2015.

24. Gatto S, Gimigliano F, Gimigliano R, Iolascon G. Prevention of falls and role of calcium and vitamin D. Aging clinical and experimental research. 2011;23(2 Suppl):20-1.

25. Annweiler C, Montero-Odasso M, Schott AM, Berrut G, Fantino B, Beauchet O. Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects. Journal of neuroengineering and rehabilitation. 2010;7:50.

26. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Annals of epidemiology. 2009;19(7):468-83.

27. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1999;8(5):399-406.

28. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer research. 2005;65(12):5470-9.

29. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, et al. Circulating 25- hydroxyvitamin d levels and survival in patients with colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(18):2984-91.

30. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. Journal of the National Cancer Institute. 2007;99(21):1594-602.

31. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. The American journal of clinical nutrition. 2007;85(6):1586-91.

32. Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference I. The National Academies Collection: Reports funded by National Institutes of Health. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington (DC): National Academies Press (US), National Academy of Sciences.; 1997.

33. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. The New England journal of medicine. 2005;352(4):373-9.

34. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrine-related cancer. 2005;12(3):549-83.

35. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood. 1993;82(5):1383-94.

36. Roodman GD. Pathogenesis of myeloma bone disease. Journal of cellular biochemistry. 2010;109(2):283- 91.

37. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98(13):1302-6.

38. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. Journal of the American Society of Nephrology : JASN. 2010;21(1):103-12.

39. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Current opinion in lipidology. 2007;18(1):41-6.

40. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938-42.

41. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney international. 1990;38(5):931-6.

42. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron. 1997;77(1):37-43.

43. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. The Journal of clinical endocrinology and metabolism. 2005;90(4):2122-6.

44. Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. The Journal of clinical investigation. 1983;72(5):1856-60.

45. Adams JS, Singer FR, Gacad MA, Sharma OP, Hayes MJ, Vouros P, et al. Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. The Journal of clinical endocrinology and metabolism. 1985;60(5):960-6.

46. Mason RS, Frankel T, Chan YL, Lissner D, Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med. 1984;100(1):59-61.

47. Insogna KL, Dreyer BE, Mitnick M, Ellison AF, Broadus AE. Enhanced production rate of 1,25- dihydroxyvitamin D in sarcoidosis. The Journal of clinical endocrinology and metabolism. 1988;66(1):72- 5.

48. Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, et al. gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. The Journal of clinical endocrinology and metabolism. 1997;82(7):2222-32.

49. Hendy GN, D'Souza-Li L, Yang B, Canaff L, Cole DE. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Human mutation. 2000;16(4):281-96.;2-a

50. Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone. 1997;20(4):303- 9.

51. Medarov BI. Milk-alkali syndrome. Mayo Clinic proceedings. 2009;84(3):261-7.

52. Adams ND, Gray RW, Lemann J, Jr. The effects of oral CaCO3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. The Journal of clinical endocrinology and metabolism. 1979;48(6):1008-16.

53. Grober U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol. 2012;4(2):158-66.

54. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. The Journal of clinical investigation. 2005;115(1):177-86.

55. Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. The Journal of clinical investigation. 2005;115(1):32-4.

56. Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics. 2008;9(11):1695-709.

57. Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. British medical journal. 1970;4(5727):69-72.

58. Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. British medical journal. 1970;4(5727):73-6.

59. Bell RD, Pak CY, Zerwekh J, Barilla DE, Vasko M. Effect of phenytoin on bone and vitamin D metabolism. Annals of neurology. 1979;5(4):374-8.

60. Mimaki T, Walson PD, Haussler MR. Anticonvulsant therapy and vitamin D metabolism: evidence for different mechanisms for phenytoin and phenobarbital. Pediatric pharmacology (New York, NY). 1980;1(2):105-12.

61. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proceedings of the American Thoracic Society. 2005;2(4):334-9; discussion 40-1.

62. Fortenbery EJ, McDermott MT, Duncan WE. Effect of theophylline on calcium metabolism and circulating vitamin D metabolites. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1990;5(4):321-4.

63. Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, MacIntyre I, Park BK. Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clinical pharmacology and therapeutics. 1981;30(3):363-7.

64. Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, Stevenson JC, MacIntyre I, et al. Effect of rifampicin and isoniazid on vitamin D metabolism. Clinical pharmacology and therapeutics. 1982;32(4):525-30.

65. Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, et al. An inducible cytochrome P450 3A4- dependent vitamin D catabolic pathway. Molecular pharmacology. 2012;81(4):498-509.

66. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47(3):510-5.

67. Bengoa JM, Bolt MJ, Rosenberg IH. Hepatic vitamin D 25-hydroxylase inhibition by cimetidine and isoniazid. The Journal of laboratory and clinical medicine. 1984;104(4):546-52.

68. Odes HS, Fraser GM, Krugliak P, Lamprecht SA, Shany S. Effect of cimetidine on hepatic vitamin D metabolism in humans. Digestion. 1990;46(2):61-4.

69. Schachter D, Finkelstein JD, Kowarski S. Metabilism of vitamin D. I. Preparation of radioactive vitamin D and its intestinal absorption in the rat. The Journal of clinical investigation. 1964;43:787-96.

70. Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D3 and calcium. Gut. 1969;10(9):717-22.

71. DiPiro JT. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill Medical; 2008.

72. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-22.

74. van der Wiel HE, Lips P, Huijgens PC, Netelenbos JC. Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover. Bone and mineral. 1993;22(1):27-32.

74. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 1996;88(4):1314-20.

75. Dahlman T, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. British journal of obstetrics and gynaecology. 1990;97(3):221-8.

76. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. American journal of obstetrics and gynecology. 1993;168(4):1265-70.

77. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. American journal of obstetrics and gynecology. 1994;170(5 Pt 1):1315-20.

78. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and haemostasis. 1994;71(1):7-11.

79. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and haemostasis. 2002;87(2):182-6.

80. Backos M, Rai R, Thomas E, Murphy M, Dore C, Regan L. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Human reproduction (Oxford, England). 1999;14(11):2876-80.

81. Mutoh S, Takeshita N, Yoshino T, Yamaguchi I. Characterization of heparin-induced osteopenia in rats. Endocrinology. 1993;133(6):2743-8.

82. Haram K, Hervig T, Thordarson H, Aksnes L. Osteopenia caused by heparin treatment in pregnancy. Acta obstetricia et gynecologica Scandinavica. 1993;72(8):674-5.

83. Aarskog D, Aksnes L, Lehmann V. Low 1,25-dihydroxyvitamin D in heparin-induced osteopenia. Lancet ( London, England). 1980;2(8195 pt 1):650-1.

84. Rizwan MM, Perrier ND. Long-term lithium therapy leading to hyperparathyroidism: a case report. Perspectives in psychiatric care. 2009;45(1):62-5.

85. Ananth J, Dubin SE. Lithium and symptomatic hyperparathyroidism. Journal of the Royal Society of Medicine. 1983;76(12):1026-9.

86. Turan MT, Esel, E., Tutus, A, et al. Lithium-induced alterations in parathormone function in patients with bipolar disorder. J Clin Psychopharm. 2001;11(2):96-100.

87. Parfitt AM. The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism. The Journal of clinical investigation. 1972;51(7):1879-88.

88. O'Connell TX. Hypercalcemia induced by tamoxifen. American journal of surgery. 1981;141(2):277-8.

89. Mulvenna PM, Wright AJ, Podd TJ. Life-threatening tamoxifen-induced hypercalcaemia. Clinical oncology (Royal College of Radiologists (Great Britain)). 1999;11(3):193-5.

90. Davis HL, Jr., Wiseley AN, Ramirez G, Ansfield FJ. Hypercalcemia complicating breast cancer. Clinical features and management. Oncology. 1973;28(2):126-37.

91. Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981;47(12):2803-6.;2-a

92. Scott M, Gelhot AR. Gastroesophageal reflux disease: diagnosis and management. American family physician. 1999;59(5):1161-9, 99.

93. Moon J, Davison A, Bandy B. Vitamin D and aluminum absorption. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 1992;147(9):1308, 13.

94. Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. The American journal of physiology. 1985;249(2 Pt 1):G209-13.

95. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, et al. 1,25- Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer research. 1999;59(4):862-7.

96. Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgraduate medical journal. 1999;75(887):554-6.

97. Commerford PJ, Lloyd EA. Arrhythmias in patients with drug toxicity, electrolyte, and endocrine disturbances. The Medical clinics of North America. 1984;68(5):1051-78.

98. Carpenter C, May ME. Case report: cardiotoxic calcemia. The American journal of the medical sciences. 1994;307(1):43-4.

Citation Information
Dana Lycans, Elias Salloum, Matthew K Wingate, Thomas Melvin, et al.. "Vitamin D Deficiency: "At Risk" Patient Populations and Potential Drug Interactions" p. 47
Available at: